Medtronic stock holds steady as Q4 FY26 revenue exceeds consensus

Traders Union
All News
Financial News
Medtronic gains 0.7% after Q4 beat

Highlights

Medtronic's Q4 fiscal 2026 revenue beat Street expectations, signaling operational outperformance that could lift near-term cash flow and support shares.
EPS fell 4.3% year-over-year, pressured by portfolio charges related to the Blackstone/MiniMed separation, but the company raised its dividend for a 49th consecutive year and plans a diabetes unit spin-off.
Technical signals remain bearish with MDT trading below major averages; downside risk dominates with an expected range between $75.88 and $80.47 in coming sessions.

Earnings drag persists as portfolio changes boost yield appeal

Medtronic's fourth-quarter fiscal 2026 revenues exceeded both TD Cowen and Street estimates, highlighting stronger operating results that may drive improved near-term cash flow and support share demand. While earnings per share matched consensus at $1.55, this reflected a 4.3% year-over-year decline due in part to a $0.12 charge associated with the Blackstone and MiniMed separation, signaling that portfolio adjustments continue to weigh on overall profitability. The company also increased its quarterly dividend to $0.72, marking the forty-ninth consecutive annual increase and reinforcing its yield-oriented appeal, alongside ongoing plans to fully exit its diabetes business by spinning off MiniMed. Together, these factors contextualize the intraday recovery by connecting corporate actions to renewed investor interest.

Bearish bias builds as seller pressure meets firm resistance

On the technical front, MDT is trading below the MA-20 ($80.12), MA-50 ($80.52), and the long-term MA-200 ($91.98) on the hourly chart. The Ichimoku Kijun sits at $79.70, marking immediate resistance. Momentum remains bearish with the MACD generating a Sell signal and the ADX indicating Neutral trend strength. The RSI is in Sell territory, while CCI and BBP both flag oversold and seller-dominant conditions intraday. Stoch RSI is Neutral, and the Awesome Oscillator also signals selling pressure.

Downside favored as resistance holds and volatility constrains upside

Over the next few trading days, MDT is expected to fluctuate within a typical volatility band between $75.88 and $80.47. Statistical scenarios currently favor a downward move (62% probability of downside versus 38% for a rebound), keeping the price constrained below resistance. If resistance at $79.70 is cleared, a recovery could unfold; however, a move below the $75.88 support would increase the risk of further declines.

Anton Kharitonov, Traders Union expert, sees Medtronic’s revenue beat and dividend hike providing limited support amid broader technical weakness. Despite positive operating news, he notes that the price remains trapped below key moving averages and resistance levels, with momentum and sentiment indicators pointing to persistent downside risks. Cautious investors may remain sidelined as the stock struggles to regain its footing. "Until $79.70 is convincingly reclaimed, I do not trust any rebound attempts in MDT."

Source of Data: MDT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.